Physician profile
John Eastman
NPI 1720608912
$726.08
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $357 · 2022: $369.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $145.00 | 2021 | |
| Lilly USA, LLC | $111.35 | 2021-2022 | |
| Esperion Therapeutics, INC. | $93.05 | 2022 | |
| Antares Pharma, INC. | $65.81 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $64.43 | 2021-2022 | |
| Amgen INC. | $49.72 | 2022 | |
| Sanofi-Aventis U.S. LLC | $48.27 | 2021-2022 | |
| Novo Nordisk INC | $42.89 | 2021-2022 | |
| Abbott Laboratories | $40.63 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.80 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.65 | 2021 | |
| Dexcom, INC. | $14.14 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.34 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Eastman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.